AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28689852
Drug: Integrated cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated cognitive behavioral therapy for co-occurring opioid use disorder and anxiety disorders
Trial: 28689852
Drug: Active comparison
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparison treatment targeting opioid use disorder alone
Trial: 16772353
Drug: Ghrelin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ghrelin (10 pmol/kg.min) infusion for 180 min
Trial: 10694094
Drug: Specific antiglycolipid
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific antiglycolipid antibodies in serum and circulating immune complexes
Trial: 10694094
Drug: IgG antibody
RxNorm normalized name: CM1 IgG antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibody levels against glycolipid LOS
Trial: 10694094
Drug: IgG antibody
RxNorm normalized name: CM1 IgG antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG antibody against LOS
Trial: 10694094
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of antigens tested in serum
Trial: 10694094
Drug: Detection of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detection of immune complexes and IgG antibodies against glycolipid antigens
Trial: 3233058
Drug: Amoxicillin 40
RxNorm normalized name: amoxicillin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 40 mg.kg‐1 every 12 hours by IV route
Trial: 3233058
Drug: Amoxicillin 40
RxNorm normalized name: amoxicillin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 40 mg.kg‐1 every 12 hours by oral route
Trial: 29247809
Drug: IV diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV diclofenac (two doses of 75mg in the first 24h after diagnosis)
Trial: 23791063
Drug: Tulobuterol patch
RxNorm normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol patch
Trial: 23791063
Drug: Oral salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral salbutamol sulfate
Trial: 21612452
Drug: Experimental green
RxNorm normalized name: acid green 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental green tea extract (40 mL, rinsed for 1 minute, three times a day for a week)
Trial: 21612452
Drug: Placebo mouth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouth rinse (40 mL, rinsed for 1 minute, three times a day for a week)
Trial: 14535872
Drug: OAC7 (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC7 (omeprazole 20 mg b.d., amoxicillin 1000 mg b.d., clarithromycin 500 mg b.d. for 7 days)
Trial: 14535872
Drug: OAC14 (clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC14 (clarithromycin 500 mg b.d. for 14 days)
Trial: 6425480
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation with total parenteral nutrition (120% of estimated energy requirements, 3.75% or 22.5% as lipid, amino acids 2.5 gm/120 kcal)
Trial: 6425480
Drug: Post-parenteral nutrition
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-parenteral nutrition period
Trial: 29514712
Drug: Sirukumab 50
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 50 mg q4w
Trial: 24699939
Drug: Sirukumab 100
RxNorm normalized name: Sirukumab
DrugBank: Sirukumab (DB11803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirukumab 100 mg q2w
Trial: 24434117
Drug: Creatine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (20 g/d for 7 d)
Trial: 16019358
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (CEE) alone
Trial: 28001147
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation with 2 g of Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032
Trial: 26414563
Drug: Caloric titration
RxNorm normalized name: Chloric acid
DrugBank: Chloric acid (DB14150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caloric titration method (CTM)
Trial: 21349747
Drug: Anti-hypertensive drugs
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-hypertensive drugs
Trial: 15026849
Drug: Data mining
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Data mining methods for predicting IVS thickness clusters ('small' or 'large') using a clusterbase/rulebase combination.
Trial: 11297240
Drug: Edatrexate 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edatrexate 40 mg/m2 weekly with cisplatin 120 mg/m2 every 4 weeks (Schedule A)
Trial: 26080804
Drug: Almond consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond consumption (85 g/day) added to a National Cholesterol Education Program (NCEP) Step 1 diet (ALM) for 6 weeks
Trial: 31471313
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg/day
Trial: 17076604
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg 1 hour before surgery and 12 hours after the first dose
Trial: 17076604
Drug: Dexamethasone 4
RxNorm normalized name: dexamethasone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 4 mg 1 hour before surgery and 8 hours after the first dose
Trial: 14756620
Drug: Cognitive-behavioral self-help
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral self-help treatment
Trial: 364037
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D dietary supplement
Trial: 30909946
Drug: Starting antiplatelet
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting antiplatelet therapy
Trial: 28756569
Drug: Intratympanic corticosteroids
RxNorm normalized name: ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intratympanic corticosteroids (administered three times every other day)
Trial: 25274428
Drug: MPH-MLR 80
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MPH-MLR 80 mg once daily
Trial: 25274428
Drug: IR methylphenidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR methylphenidate 25 mg three times daily
Trial: 22342396
Drug: 3-day albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-day albendazole therapy
Trial: 22342396
Drug: 15-day albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15-day albendazole therapy
Trial: 22342396
Drug: Albendazole therapy
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole therapy (both durations)
Trial: 15623768
Drug: Full treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full treatment with glasses and occlusion
Trial: 10197852
Drug: 12-week course
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week course of 300 mg of cyproterone acetate daily followed by surgery (CPA)
Trial: 24953249
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical nerve stimulation (TENS) for 60 minutes before 30 minutes of physical therapy
Trial: 24953249
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with 30 minutes of physical therapy alone
Trial: 19454639
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) alone during maintenance
Trial: 19454639
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) plus zolpidem during maintenance
Trial: 15219195
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (STEMI patients treated by PTCA without GPIIb-IIIa antagonist)
Trial: 12217810
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose anti-thymocyte globulin (ATG) as first-line treatment within 14 days of diagnosis
Trial: 12217810
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose anti-thymocyte globulin (ATG) as second-line therapy more than 14 days after diagnosis
Trial: 12217810
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose anti-thymocyte globulin (ATG) late treatment group
Trial: 12217810
Drug: Concurrent control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent control group (not treated with ATG)
Trial: 10354716
Drug: Corticosteroids treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids treatment in patients with idiopathic pulmonary fibrosis and avian fancier's lung
Trial: 10354716
Drug: Corticosteroids treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids treatment in sarcoidosis patients
Trial: 10354716
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment in pulmonary fibrosis patients
Trial: 10354716
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment in sarcoidosis patients
Trial: 10354716
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment in avian fancier's lung patients
Trial: 10499883
Drug: Repaglinide 1
RxNorm normalized name: repaglinide 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide 1 mg before each meal
Trial: 668784
Drug: Oral chlordiazepoxide
RxNorm normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral chlordiazepoxide hydrochloride (50 mg)
Trial: 22105254
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (75 micrograms)
Trial: 9416950
Drug: Enalapril (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (up to 40 mg)
Trial: 8387087
Drug: Oral instructions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral instructions indicating no change in blood pressure
Trial: 3030946
Drug: Trimethoprim-polymyxin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-polymyxin B sulfate cream
Trial: 16686722
Drug: Solifenacin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin (5 mg)
Trial: 20805450
Drug: Multivitamin use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin use during adjuvant chemotherapy
Trial: 20805450
Drug: Multivitamin use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin use reported 6 months after completion of adjuvant chemotherapy
Trial: 16203942
Drug: Lifestyle-focused, fitness-oriented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lifestyle-focused, fitness-oriented gym classes (treatment group)
Trial: 7491818
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with Mycobacterium w vaccine
Trial: 2110437
Drug: Fleroxacin 200
RxNorm normalized name: fleroxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 200 mg for 10 days
Trial: 2110437
Drug: Fleroxacin 400
RxNorm normalized name: fleroxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 400 mg for 10 days
Trial: 2110437
Drug: Fleroxacin 600
RxNorm normalized name: fleroxacin
DrugBank: Fleroxacin (DB04576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin 600 mg for 10 days
Trial: 3001664
Drug: d-amphetamine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine (10 mg)
Trial: 1147869
Drug: placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (no drug)
Trial: 31600243
Drug: Oral B-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral B-12 2μg/day with multiple micronutrients (UNIMAPP formula + 20gm milk powder)
Trial: 21921362
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg/day for 8 weeks, titrated to a maximum of 100 mg/day)
Trial: 21921362
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no vildagliptin administered)
Trial: 8427432
Drug: Midazolam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (1 mg/mL) administered until desired sedation achieved (max 5 mL)
Trial: 8427432
Drug: Diazepam (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (2.5 mg/mL) administered until desired sedation achieved (max 5 mL)
Trial: 3116290
Drug: Intravenous branched
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous branched chain amino acid (BCAA) diet (60-80 g/day, BCAA content 51%, energy 2000 kcal/day)
Trial: 3116290
Drug: Nasogastric (NG)
RxNorm normalized name: NG
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasogastric (NG) branched chain amino acid (BCAA) diet (amino acids 58 g, BCAA 43%, oligopeptides 19.5 g, energy 2000 kcal/day)
Trial: 27647071
Drug: rhGM‐CSF gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhGM‐CSF gel
Trial: 25759404
Drug: Tianeptine (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tianeptine (12.5 mg)
Trial: 2890364
Drug: Tubocurarine 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubocurarine 0.05 mg kg‐1
Trial: 2890364
Drug: Vecuronium 0.012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.012 mg kg‐1
Trial: 27436226
Drug: Self-expansion during
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-expansion during treatment
Trial: 17267927
Drug: 1.2 g
RxNorm normalized name: Humidifier 1.2 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 g eicosapentaenoic acid plus 0.9 g decosahexaenoic acid (n=22)
Trial: 15078794
Drug: ML PENTA
RxNorm normalized name: 1 ML pentazocine 30 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ML PENTA stent
Trial: 10855739
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 8-16 mg once daily
Trial: 3128139
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 at a dosage of 0.2 mg (2 ml)
Trial: 24429540
Drug: Crystalline amino
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalline amino acid mixture with protein intakes of 0.1, 0.3, 0.6, 0.9, 1.2, 1.5, or 1.8 g · kg⁻¹ · d⁻¹
Trial: 18477493
Drug: Mifepristone tablet
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mifepristone tablet (75 mg)
Trial: 10915400
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V suspension 13.3 mg/kg three times daily for 10 days
Trial: 1686562
Drug: GR122311X 196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR122311X 196 mg b.d.
Trial: 1686562
Drug: GR122311X 391
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR122311X 391 mg b.d.
Trial: 1686562
Drug: GR122311X 782
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR122311X 782 mg b.d.
Trial: 8218755
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg ranitidine b.d.
Trial: 6662004
Drug: Indomethacin 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 0.5% solution eyedrops
Trial: 27164985
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg for 3 days prior to surgery (including the day of surgery)
Trial: 24360571
Drug: peginterferon α‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: peginterferon α‐2a + RBV 1600 mg/day + epoetin β (B2; n=13)
Trial: 20461765
Drug: Gemcitabine 175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 175 mg/m(2) on days 1, 5, 29, and 33, cisplatin 20 mg/m(2) on days 1‐5 and 29‐32, 5‐FU 600 mg/m(2) on days 1‐5 and 29‐32, followed by radiation with continuous infusion 5‐FU 225 mg/m(2) for 6 weeks
Trial: 16133138
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C with atypical antipsychotics
Trial: 16133138
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with atypical antipsychotics
Trial: 12924045
Drug: Chemoradiotherapy (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (50 to 60 Gy of radiotherapy plus concurrent chemotherapy with 5-fluorouracil (5-FU) plus cisplatin)
Trial: 10229251
Drug: Additional preparatory
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional preparatory measures (dietary restrictions and phospho-soda oral saline laxative)
Trial: 1867076
Drug: Indomethacin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.2 mg/kg body weight infused over 5 min)
Trial: 27619750
Drug: Evolocumab (420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab (420 mg, monthly subcutaneous)
Trial: 11110009
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg, 100 mg, or 200 mg)
Trial: 21715446
Drug: Conventional heart
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional heart failure treatment
Trial: 28028768
Drug: Betaine HCl
RxNorm normalized name: betaine HCl
DrugBank: Betaine (DB06756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betaine HCl (1500 mg) after rabeprazole pretreatment
Trial: 22654431
Drug: Rabeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (20 mg twice daily)
Trial: 26589718
Drug: Individual completeness
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual completeness of chemotherapy rate
Trial: 20467406
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid (HA) injections (average molecular weight 1.5 million Da), 3 injections at weeks 1, 2, and 3
Trial: 18384679
Drug: Etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg daily
Trial: 16005691
Drug: Coreg from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coreg from Roche Químicos e Farmacêuticos S.A standard reference formulation
Trial: 1720828
Drug: Ro 42‐5892
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 42‐5892 (10‐min infusion, doses ranging from 0.001 to 1 mg/kg)
Trial: 1720828
Drug: Ro 42‐5892
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 42‐5892 (100, 600, or 1,200 mg p.o.)
Trial: 1720828
Drug: Ro 42‐5892
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 42‐5892 (1,200 mg p.o.)
Trial: 6758833
Drug: Prednisone 30
RxNorm normalized name: prednisone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 30 mg daily given orally for two weeks
Trial: 8806338
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug therapy (Control)
Trial: 24216721
Drug: Probucol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (500 mg/day) and cilostazol (200 mg/day) with behavioral modifications
Trial: 24216721
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg/day) with behavioral modifications (control group)
Trial: 24216721
Drug: Probucol and
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probucol and cilostazol treatment
Trial: 17392464
Drug: No patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No patch (matched nonsmokers)
Trial: 15971426
Drug: Air-steroid-saline mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air-steroid-saline mixture as contrast medium
Trial: 10637949
Drug: Randomised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomised treatment within 6 hours
Trial: 7737560
Drug: Omeprazole, 20
RxNorm normalized name: Omeprazole, 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, 20 mg daily for one week
Trial: 25808572
Drug: Lornoxicam 8
RxNorm normalized name: lornoxicam 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lornoxicam 8 mg